

Fibromyalgia syndrome

‘A dose of the flu that lasts forever’

ERIC VISSER MB BS, FANZCA, FPPMANZCA, MACE

Fibromyalgia syndrome results in widespread pain and other symptoms related largely to dysregulation of the neuroimmune system. It is often described by patients as ‘feeling like a never-ending dose of the flu’. It can be regarded as a chronic stress-or-sickness response and should be managed using a multimodal approach.

Key points

- People with fibromyalgia syndrome (FMS) present with chronic widespread pain, fatigue, sleep disturbance, sensory sensitivity and psychocognitive dysfunction.
- In FMS there is evidence of psychoneuroimmune, cortical and endocrine dysfunction and in some cases widespread small-fibre polyneuropathy.
- Illness, stress, duress and trauma are common triggers of FMS, and there is a strong link to mood and anxiety disorders.
- The whole person with FMS should be managed using a biomedical psychosocial approach.

PAIN MANAGEMENT TODAY 2017; 4(2): 24-26

Professor Visser is Churack Chair of Chronic Pain Education and Research at the University of Notre Dame Australia, Perth, and a Specialist Pain Medicine Physician and Anaesthesiologist at PainScience, Joondalup Health Campus, Joondalup, and St John of God Hospital, Subiaco, WA.



Case scenario

A 43-year-old woman presents with an 18-month history of widespread body and neck pain, chronic fatigue, sleep disturbance and altered mood after a whiplash-associated neck injury from a motor vehicle accident. She has flashbacks and dreams of the crash, has lost her job and is involved in legal action for compensation. She feels like she has a ‘dose of the flu that is lasting forever’.

Fibromyalgia is a clinical syndrome with a spectrum of symptoms, including chronic widespread pain and fatigue, sleep disturbance, altered mood and cognitive and neurosensory dysfunction (see Table). Fibromyalgia syndrome (FMS) may be considered a chronic stress-or-sickness response, triggered by a variety of physiological or psychological stressors.

Diagnostic criteria for FMS are based on the number of body regions affected by pain and the severity of systemic symptoms.¹ FMS affects up to 8% of the population, most commonly women between 30 and 60 years of age.^{2,3} About 30% of patients with a localised chronic pain disorder develop FMS. The incidence of FMS is increased in patients with bipolar disorder, anxiety, depression or a family history of FMS.³

Proposed mechanisms

FMS may be considered to be part of a spectrum of systemic stress disorders with similar mechanisms and aetiologies. These disorders include chronic fatigue syndrome, myalgic encephalitis, chemical sensitivity syndrome and Gulf War syndrome. The term fibromyalgia (meaning painful fibromuscular tissues) is a historically outdated term from a time when the condition was considered to be a muscle disorder.¹

Stress and allostatic load

Organisms, including humans, have evolved systems to deal with threats against their viability. These threats are known as ‘stressors’ – that is, any factor that alters normal homeostasis (functional balance). Stressors can apply to the organism as a whole or to a specific organ system. The cumulative effect of stressors on homeostasis and tissue viability is known as allostatic load.^{2,3}

An organism can generate a set of defensive stress responses to counter allostatic load. Pain, fear, nausea and itch are examples of targeted stress responses that protect an organism from tissue damage.⁴ The acute stress response ('fight or flight') is the best-known rapid defence system that protects an organism from imminent threat.²⁻⁴

An organism can only maintain the energy-demanding acute stress response for a few hours at a time. If exposed to prolonged or overwhelming stress, the organism will instead initiate a chronic stress response, known as the sickness response.⁵ Organisms, including humans, can accumulate an allostatic load over a lifetime. After stress exposure, the organism incurs an 'allostatic debt', because homeostasis never fully returns to pre-stress levels. As a consequence, less allostatic load is required to trigger a subsequent sickness response.³⁻⁵

FMS as a chronic stress-or-sickness response

FMS may be thought of as a whole-body chronic stress-or-sickness response, triggered by a range of physiological or psychological stressors (biomedical, psychosocial and environmental). Common stressors include trauma or injury (e.g. whiplash neck injury), illness (e.g. cancer, arthritis or influenza) and adverse life events (e.g. childhood duress or post-traumatic stress disorder [PTSD]). It does not matter if a stressor is psychological, environmental or pathological; the body will respond in the same way – with an acute or chronic stress response.⁴

Visser and Davies proposed that the sickness response is part of a whole-body defence system (the 'threat matrix'), which generates polymodal responses (pain, nausea, experiences of noxious heat or cold, itch, panic, dyspnoea, fatigue, dissociative states) in response to any threat to a person's viability.⁴

The sickness response and its clinical manifestation, FMS, are characterised by significant changes in the body's neurological, immune and endocrine systems. These changes are associated with widespread body pain and other symptoms, such as chronic fatigue, sleep disturbance, heightened

Body system, symptoms	Features and proposed mechanisms
Widespread body pain 'Too sore to move'	<ul style="list-style-type: none"> • Pain in neck, shoulders, spine, gluteal muscles (worse after exercise) • Allodynia (touch pain) in skin, soft tissues • Central sensitisation, impaired inhibition of nociception • Neuroimmune activation, nonrestorative sleep • Small-fibre polyneuropathy
Related pain disorders	<ul style="list-style-type: none"> • Whiplash-associated neck pain, restless legs, irritable bowel syndrome, overactive bladder, temporomandibular joint disorder, headache, sinusitis, complex regional pain syndrome
Chronic fatigue 'Too tired to move'	<ul style="list-style-type: none"> • Sleep disturbance, reduced exercise tolerance, mitochondrial dysfunction, oxidative stress, low cortisol or vitamin D levels, depression
Lack of motivation	<ul style="list-style-type: none"> • Reduced motivation for work, recreation; reduced appetite, libido • Fatigue, increased time sleeping, dyscognia, depression, low dopamine or cortisol levels
Sleep disturbance 'Too tired to sleep'	<ul style="list-style-type: none"> • Nonrestorative sleep • Dysfunction of HPA axis, altered levels of neurotransmitters (e.g. serotonin, melatonin), depression, PTSD
Sensory sensitivity Hypervigilance	<ul style="list-style-type: none"> • Heightened sensitivity to light (photophobia; patients describe fluorescent light tubes that seem to 'flicker and hum'), sound (hyperacusis, tinnitus), touch (allodynia, paraesthesia), temperature (cold), odours, chemicals, toxins, drugs
Autonomic nervous system	<ul style="list-style-type: none"> • Postural hypotension, tachycardia, vasoactive effects (flushing, Raynaud's syndrome), constipation, diarrhoea • Dysfunction of HPA axis, altered levels of neurotransmitters
Cognitive symptoms 'Too tired to think'	<ul style="list-style-type: none"> • Poor memory, impaired concentration and thinking ('fibro-fog')
Psychological symptoms	<ul style="list-style-type: none"> • Bipolar disorder, anxiety, PTSD, depression, substance misuse • Genetic polymorphisms in the serotonergic, dopaminergic and catecholaminergic systems • Developmental trauma or duress (in childhood)
Immune system	<ul style="list-style-type: none"> • Sinusitis, skin reactions, gut dysfunction, drug sensitivities • Activation of glia, monocytes, mast cells, Toll-like receptors; increased secretion of cytokines, antibodies; altered gut microbiome
Medical disorders	<ul style="list-style-type: none"> • Chronic fatigue syndrome, myalgic encephalitis, chemical sensitivity, joint hypermobility, post-infectious disease syndrome, rheumatological and autoimmune symptoms, cancer

Abbreviations: HPA = hypothalamic-pituitary-adrenal axis; PTSD = post-traumatic stress disorder.

responses to sensory stimuli (e.g. cold, light and sound), lack of energy and motivation, difficulty thinking, poor memory, depression, anxiety and reduced appetite and libido.³

Many people will have experienced the feeling of the sickness response and FMS when they have had a cold or flu. The sickness response could be described as a 'hibernation' response, to conserve energy and re-establish

homeostasis, as an adaptation to stress. This is clearly an adaptive response when we are fighting an infection, and the response only lasts a few days. However, if a person is exposed to overwhelming or long-term stress, the sickness response may persist for a prolonged period. It then becomes maladaptive and may manifest clinically as FMS.

Pathophysiology

Neuroimmune dysfunction

The neuroimmune system is activated with glia, macrophages, monocytes, mast cells and neurons, which produce mediators (cytokines, antibodies and neuropeptides, such as substance P) that contribute to the chronic sickness response.²⁻⁶ Toll-like receptors (TLRs) play a key role in regulating the innate immune system. Pilot studies have shown that TLR-blocking agents such as naltrexone and melatonin may have a clinical effect in FMS and inflammatory diseases such as Crohn's disease, but these treatments are still considered experimental.⁶

Central versus peripheral nervous system effects

In FMS, the body's nociceptive system becomes sensitised and responses are amplified, in a process known as central sensitisation. Inhibitory nociceptive systems also become less effective. Patients with FMS show reduced tolerance to noxious stimuli and heightened sensitivity to non-noxious stimuli, with altered neuroprocessing of touch, pressure, temperature, sound and chemical stimuli.⁷

FMS is largely a CNS neuroprocessing disorder. It is characterised by widespread pain reflecting cutaneous, somatic and visceral allodynia. Wolfe's classic tender points for fibromyalgia represent reproducible sites of pressure-evoked pain.⁸ However, the peripheral nervous system may also be involved, with recent studies suggesting that at least 30% of patients with FMS have small-fibre sensory polyneuropathy which may cause neuropathic pain.⁹

Cortical and autonomic changes

Functional neuroimaging has shown cortical and thalamic changes in patients with FMS,

and there is evidence of dopaminergic neurotransmitter dysfunction in the limbic system. There is also evidence of significant autonomic nervous system dysfunction (postural hypotension and altered heart rate variability, including postural orthostatic tachycardia syndrome) and an impaired sympathetic response to stress.³ Sleep disturbance and hypothalamic dysfunction are also key features of the sickness response and FMS. These features are associated with electroencephalographic changes and sleep-disordered breathing.³

Endocrine dysfunction

Patients who have FMS show impaired hypothalamic-pituitary-adrenal axis responses to stress. There are changes to the levels of some hormones (growth hormone and cortisol) and of various neurotransmitters which control nociception, mood and sleep (substance P, noradrenaline, serotonin, melatonin, nerve growth factor and dynorphin).³

Altered gut microbiome and free radical production

FMS, and related conditions such as chronic fatigue syndrome, may be associated with dysfunction of the gut-brain axis and the microbiome. Altered mitochondrial energy processing, particularly in skeletal muscle, and the overproduction of oxygen and nitrogen free-radical species may also be associated with these syndromes.¹⁰

Psychosocial factors

There is a strong correlation between FMS and mood disorders among patients and their families. The strongest correlations are with bipolar disorder, obsessive-compulsive disorder and PTSD.¹¹ FMS has been shown to be associated with genetic polymorphisms in the serotonergic, dopaminergic and catecholaminergic systems of pain transmission and processing, which are also implicated in mood disorders.¹²

The incidence of stressful life events in childhood or adolescence, particularly before the onset of symptoms, is significantly higher in patients with FMS compared with healthy controls and people with rheumatoid

arthritis.¹¹ For a patient with FMS, their psychosocial stressor load and their use of health-care resources are also significantly greater if more than 20% of their body surface area is affected by pain, as drawn on a body diagram.¹³

The links between psychological stress and FMS are likely to be multifactorial but there are certainly neurobiological contributors. Patients with hypothalamic-pituitary-adrenal axis dysfunction (impaired dexamethasone suppression and abnormal diurnal cortisol levels) are at significantly increased risk of developing chronic widespread pain.¹⁴ Chronic psychological stress generates cytokines which (via neuroimmune mechanisms) may produce anxiety, depressed mood and widespread pain; the hallmarks of FMS.¹⁵

Conclusion

The patient in the case scenario is representative of the most common population in which FMS occurs (women between 30 and 60 years of age). She reports key symptoms (pain, fatigue and neurosensory dysfunction) and was exposed to a significant allostatic load. Her cumulative stressors include a motor vehicle accident, chronic pain and illness, PTSD, and social, legal and financial issues. She also reports two of the most prevalent clinical conditions associated with FMS, whiplash-associated neck pain and PTSD. Finally, the description of how she feels, as if she has an ongoing dose of the flu, reflects the chronic sickness response her body is mounting to deal with her stressor load.

FMS is a prime example of a complex biomedical, psychosocial and environmental syndrome associated with whole-person physiological and psychocognitive effects. It is largely a chronic sickness response to an allostatic load in a vulnerable person. Therefore, management of patients must reflect the complex aetiology of the condition by using a whole-person, multimodal approach. **PMT**

References

A list of references is included in the online version of this article (www.painmanagementtoday.com.au).

COMPETING INTERESTS: None.

Fibromyalgia syndrome

‘A dose of the flu that lasts forever’

ERIC VISSER MB BS, FANZCA, FFPMANZCA, MACE

References

1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. *Semin Arthritis Rheum* 2016; 46: 319-329.
2. Thiagarajah AS, Guymmer EK, Leech M, Littlejohn GO. The relationship between fibromyalgia, stress and depression. *Int J Clin Rheumatol* 2014; 9: 371-384.
3. Clauw DJ. Fibromyalgia: a clinical review. *JAMA* 2014; 311: 1547-1555.
4. Visser EJ, Davies S. Expanding Melzack's pain neuromatrix: the threat matrix: a super-system for managing polymodal threats. *Pain Pract* 2010; 10: 163.
5. Lyon P, Cohen M, Quintner J. An evolutionary stress-response hypothesis for chronic widespread pain (fibromyalgia syndrome). *Pain Med* 2011; 12: 1167-1178.
6. Nicotra L, Loram LC, Watkins LR, Hutchinson MR. Toll-like receptors in chronic pain. *Exp Neurol* 2012; 234: 316-329.
7. Potvin S, Marchand S. Pain facilitation and pain inhibition during conditioned pain modulation in fibromyalgia and in healthy controls. *Pain* 2016; 157: 1704-1710.
8. Cagnie B, Coppieters I, Denecker S, Six J, Danneels L, Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. *Semin Arthritis Rheum* 2014; 44: 68-75.
9. Wang SJ, Chou RC. AB0842 Relationship of fibromyalgia syndrome, diffuse pain, and small fiber peripheral neuropathy [abstract]. *Ann Rheum Dis* 2016; 75: 1191.
10. Sánchez-Domínguez B, Bullón P, Román-Malo L, et al. Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with fibromyalgia. *Mitochondrion* 2015; 21: 69-75.
11. Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. *J Clin Psychiatry* 2006; 67: 1219-1225.
12. Anderberg UM, Marteinsdottir I, Theorell T, Von Knorring L. The impact of life events in female patients with fibromyalgia and in female healthy controls. *Eur Psychiatry* 2000; 15: 295-301.
13. Visser EJ, Ramachenderan J, Davies SJ, Parsons R. Chronic widespread pain drawn on a body diagram is a screening tool for increased pain sensitization, psycho-social load, and utilization of pain management strategies. *Pain Pract* 2016; 16: 31-37.
14. McBeth J, Silman AJ, Gupta A, et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. *Arthritis Rheum* 2007; 56: 360-371.
15. Maier SF. Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. *Brain Behav Immun* 2003; 17: 69-85.